GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 This proposed transaction further diversifies Zimm ...

GH Research's inhaled psychedelic therapy GH001 has shown promise in a mid-stage trial in treatment-resistant depression (TRD ...

For those with major depression, there is a new treatment option - one that offers hope when patients are not responding to existing treatment. The ...

Eldredge finally found relief. He said things immediately got better about six months ago when he tried Spravato. “It’s so life-changing,” said Eldredge. Spravato is a ketamine-derived nasal ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...

Ozempic gains expanded approval; Boxed Warning added to MS treatment label; Monotherapy approval granted to Spravato; Leqembi gains maintenance regimen; Enhertu gains new breast cancer indication.

An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

The UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal spray Spravato on the NHS, because of cost and clinical concerns.

According to the prescribing information, patients treated with Spravato should receive a dose twice a week for the first four weeks. In the following four weeks, the dosing is reduced to once per ...